Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02696889 · ClinicalTrials.gov registry record · NA
Rejuvenation of Premature Ovarian Failure With Stem Cells
A NA study of Primary Ovarian Insufficiency and Premature Ovarian Failure, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- NA
- Development phase
- 3
- Enrollment target
- 1
- Study location
NCT02696889 is a NA study of Primary Ovarian Insufficiency and Premature Ovarian Failure that has completed, run by University of Illinois at Chicago. The registered enrollment target is 3 participants, below the 184-participant average among 3 other Primary Ovarian Insufficiency trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02696889, a NA study of Primary Ovarian Insufficiency and Premature Ovarian Failure, has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
- 1
- Study location
Study Summary
The ROSE-1 study is designed to determine the efficacy of bone marrow derived stem cell therapy on ovarian function recovery in subjects with idiopathic and other types of premature or primary ovarian failure (POF or POI) and low ovarian reserves.
Conditions Studied
Interventions
- PROCEDURE ROSE-1 Protocol
Study Locations (1)
Illinois
- University of Illinois at Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2016-02-06 |
| Est. Completion | 2021-05-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02696889
The ClinicalTrials.gov registry entry for NCT02696889 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 184-participant average among 3 other Primary Ovarian Insufficiency trials with a reported enrollment target (98% lower). The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Primary Ovarian Insufficiency appearing as the primary indexed condition, and to 1 intervention - of which ROSE-1 Protocol is the first listed.
NCT02696889 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT02696889 about?
NCT02696889 is a clinical study titled "Rejuvenation of Premature Ovarian Failure With Stem Cells". The ROSE-1 study is designed to determine the efficacy of bone marrow derived stem cell therapy on ovarian function recovery in subjects with idiopathic and other types of premature or primary ovarian failure (POF or POI) and low ovarian reserves.
What is the current status of trial NCT02696889?
This trial is currently completed. It is a NA study. The enrollment target is 3 participants. The study started on 2016-02-06. Estimated completion is 2021-05-06.
What conditions does trial NCT02696889 study?
This clinical trial studies the following conditions: Primary Ovarian Insufficiency, Premature Ovarian Failure, Low Ovarian Reserve.
What interventions are being tested in trial NCT02696889?
The interventions under investigation include: ROSE-1 Protocol (PROCEDURE).
Who is sponsoring clinical trial NCT02696889?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02696889 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Ovarian Insufficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Endometrial Thickness Among Adolescent and Young Adult Patients on Estrogen Replacement Therapy Using Daily Oral Micronized Progesterone Versus the Etonogestrel Implant.
RECRUITING
-
Identifying Genome Variants in Non-Obstructive Azoospermia (NOA) or Primary Ovarian Insufficiency (POI)
RECRUITING
-
Primary Ovarian Insufficiency: Phenotype and Optimal Treatment
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.